Mersana Therapeutics to Host First Quarter 2022 Conference Call on May 9, 2022
02 mai 2022 08h00 HE
|
Mersana Therapeutics, Inc.
CAMBRIDGE, Mass., May 02, 2022 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of...
Mersana Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
06 avr. 2022 16h05 HE
|
Mersana Therapeutics, Inc.
CAMBRIDGE, Mass., April 06, 2022 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of...
Mersana Therapeutics to Present Preclinical Data on XMT-1660, XMT-2056 and the Immunosynthen Platform at AACR Annual Meeting
05 avr. 2022 08h00 HE
|
Mersana Therapeutics, Inc.
XMT-1660 demonstrates robust activity in preclinical models of breast cancer XMT-2056 demonstrates robust activity as monotherapy, in combination with standard of care therapies and in both HER2-high...
Mersana Therapeutics to Present an Analysis from the Expansion Cohort of the Phase 1 Trial of Upifitamab Rilsodotin at the Society of Gynecologic Oncology (SGO) Annual Meeting on Women’s Cancer
15 mars 2022 08h00 HE
|
Mersana Therapeutics, Inc.
CAMBRIDGE, Mass., March 15, 2022 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of...
Mersana Therapeutics to Present at the Cowen 42nd Annual Health Care Conference
02 mars 2022 08h00 HE
|
Mersana Therapeutics, Inc.
CAMBRIDGE, Mass., March 02, 2022 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc., (NASDAQ: MRSN) a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of...
Mersana Therapeutics Announces Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update
28 févr. 2022 06h00 HE
|
Mersana Therapeutics, Inc.
UPLIFT on track to complete enrollment Q3 2022, UP-NEXT to initiate in Q2 2022, and UPGRADE on track for 2H 2022 interim data readoutXMT-1660 and XMT-2056 expected to enter clinic mid-2022Research...
Mersana Therapeutics to Host Conference Call Announcing Fourth Quarter and Year End 2021 Financial Results and Business Updates
22 févr. 2022 08h00 HE
|
Mersana Therapeutics, Inc.
CAMBRIDGE, Mass., Feb. 22, 2022 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of...
Mersana Therapeutics to Present at the 11th Annual SVB Leerink Global Healthcare Conference
10 févr. 2022 08h00 HE
|
Mersana Therapeutics, Inc.
CAMBRIDGE, Mass., Feb. 10, 2022 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc., (NASDAQ: MRSN) a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of...
Mersana Therapeutics Announces Research Collaboration and License Agreement with Janssen to Advance Novel Antibody-Drug Conjugates
03 févr. 2022 07h00 HE
|
Mersana Therapeutics, Inc.
Collaboration focused on discovering novel ADCs for three targets by leveraging Mersana’s ADC expertise and the Dolasynthen platform with Janssen’s proprietary antibodiesMersana receives $40 million...
Mersana Therapeutics Announces 2022 Strategic Priorities and Milestones
07 janv. 2022 08h00 HE
|
Mersana Therapeutics, Inc.
UPLIFT, a single-arm registrational trial of UpRi in platinum-resistant ovarian cancer, expected to complete enrollment in Q3 2022 UP-NEXT, a Phase 3 trial of UpRi monotherapy maintenance in...